VD4] ENT Antilichaam

LIGHT Antibody: LIGHT, also known as Tumor Necrosis Factor Superfamily member 14 (TNFSF14), is a co-stimulatory molecule that can regulate T-cell activation (1) and has recently been identified as an immune checkpoint protein. LIGHT binds to two different receptors, Herpes Virus Entry Mediator (HVEM) and Lymphotoxin beta Receptor (LTβR) . While LIGHT binding to HVEM delivers a co-stimulatory signal to T cells (1), LIGHT binding to LTβR is critical for the formation of lymphoid structures which can stimulate T cell infiltration and activation of a tumor microenvironment, leading to rapid T cell-mediated tissue destruction (2) . It has been shown that targeted delivery of LIGHT to tumors, thereby causing the T cell infiltration of the tumor, can enhance the response of the PD-1/PD-L1 checkpoint blockade anti-cancer therapy (3), suggesting that LIGHT may become a potent tool in anti-cancer treatment.

8740

O43557

NP_003798

Human

LIGHT antibody was raised against the extracellular domain of human LIGHT.

8D4

Unconjugated

Primary Antibodies

Immunology

LIGHT Antibody is supplied as protein A purified IgG2b.

Cat. No. 1331 - Human Lymphoma Tissue Lysate

1 mg/mL

LIGHT Antibody is supplied in PBS containing 0.02% sodium azide and 50% glycerol.

None

Blue Ice

LIGHT antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

IgG2b

TNFSF14

TNF superfamily member 14

Homo sapiens

Wang Y, Zhu M, Miller M, et al. Immunoregulation by tumor necrosis factor superfamily member LIGHT. Immunological Reviews 2009; 229:232–43.

Lee Y, Chin RK, Christiansen P, et al. Recruitment and activation of naive T cells in the islets by lymphotoxin beta receptor-dependent tertiary lymphoid structure. Immunity 2006; 25:499-509.

Tang H, Wang Y, Chlewicki LK, et al. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell 2016; 29:285-296.

LIGHT Antibody: TNFSF14, LTg, CD258, HVEML, HVEM ligand

ELISA, WB, IHC-P, ICC, IF, Flow

25952144

Liquid